|1.||Schally, Andrew V: 23 articles (01/2011 - 02/2002)|
|2.||Nagy, Attila: 18 articles (06/2006 - 02/2002)|
|3.||Halmos, Gabor: 16 articles (06/2007 - 02/2002)|
|4.||Schally, A V: 11 articles (05/2008 - 02/2000)|
|5.||Nagy, A: 10 articles (01/2002 - 02/2000)|
|6.||Halmos, G: 9 articles (09/2001 - 02/2000)|
|7.||Szepeshazi, Karoly: 7 articles (06/2007 - 02/2002)|
|8.||Keller, Gunhild: 7 articles (07/2006 - 05/2005)|
|9.||Engel, Jörg B: 6 articles (07/2006 - 05/2005)|
|10.||Baker, Benjamin: 5 articles (07/2006 - 08/2005)|
07/05/2006 - "Cytotoxic radical AN-201 was toxic and had no significant effect on tumor growth. "
11/01/2005 - "AN-201 is active against tumors resistant to DOX, and noncardiotoxic. "
02/08/2002 - "In the surviving mice, AN-201 caused a 50% inhibition in tumor volume and a 27% reduction in tumor weight, which were non-significant, as compared to the controls. "
06/01/2000 - "After 5 weeks, the volumes of SW-839 and 786-0 RCC tumors were decreased by 67.2 (P < 0.05) and 78.3% (P < 0.01), respectively, whereas AN-201 had no significant effect on tumor growth. "
09/15/1998 - "Four weeks after the injection of 110 nmol/kg AN-201, mean tumor volume was reduced by 35.1 % (P < 0.05), as compared with controls. "
|2.||Prostatic Neoplasms (Prostate Cancer)
02/01/2006 - "The effects of AN-207 and AN-201 were investigated in DU-145 androgen independent and LuCaP-35 androgen sensitive human prostate cancers xenografted into nude mice. "
01/01/2006 - "Targeted analog AN-215 significantly inhibited growth of subcutaneously implanted DU-145, LuCaP-35 and MDA-PCa-2b prostate cancers by 81% to 91% compared to controls, while cytotoxic radical AN-201 was less effective and more toxic. "
02/01/2004 - "In nude mice bearing intra-osseous implanted C4-2 prostate cancers AN-238 decreased serum PSA levels by 65% compared with controls after 5 weeks of therapy (p <0.05), while AN-201 was ineffective. "
09/15/1998 - "Our study indicates that cytotoxic SST analogue AN-238 can be targeted to SSTRs on tumors and produces a powerful inhibition of the growth of Dunning-AT-1 rat prostate cancer at doses that are nontoxic, whereas its cytotoxic component, 2-pyrrolinodoxorubicin, is toxic and ineffective."
02/17/1998 - "Preliminary studies in animal models of breast and prostate cancers showed that AN-238 is less toxic than AN-201 and more potent in inhibiting tumor growth. "
02/01/2000 - "All cytotoxic compounds produced leukopenia, but the strongest lymphocyte suppression was caused by cytotoxic radical AN-201. "
06/15/1999 - "AN-201 caused the death of 1 of the 10 animals and significantly greater leukopenia than AN-207, which produced no toxic deaths. "
08/12/1999 - "Toxicity of AN-201 was much greater than that of AN-238, as measured by animal deaths, loss of body weight and leukopenia. "
|4.||Hepatocellular Carcinoma (Hepatoma)
|5.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2001 - "In the present study we investigated the cytocidal effects of AN-207 and AN-201 on the LHRH receptor-positive ES-2 ovarian cancer cells. "
01/01/2004 - "Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. "
04/11/2003 - "Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. "
10/01/2002 - "We investigated the effects of AN-207 and AN-201 on the growth of LHRH receptor-positive ES-2 human ovarian cancers. "
05/01/1999 - "Female nude mice bearing xenografts of OV-1063 ovarian cancers were treated with analog AN-207, cytotoxic radical AN-201, or agonist [D-lysine6 ]luteinizing hormone-releasing hormone. "
|4.||Gonadotropin-Releasing Hormone (GnRH)
|5.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|7.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)